What is HC Wainwright’s Forecast for OLMA FY2024 Earnings?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Olema Pharmaceuticals in a report released on Wednesday, December 11th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($2.23) per share for the year, up from their prior estimate of ($2.34). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.35) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2024 earnings at ($0.53) EPS, Q1 2025 earnings at ($0.64) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.25) EPS, FY2026 earnings at ($4.14) EPS, FY2027 earnings at ($3.84) EPS and FY2028 earnings at ($3.28) EPS.

Olema Pharmaceuticals Stock Up 0.4 %

OLMA opened at $6.75 on Friday. The firm has a market cap of $386.76 million, a P/E ratio of -3.08 and a beta of 1.92. Olema Pharmaceuticals has a 52 week low of $6.24 and a 52 week high of $16.77. The business’s fifty day simple moving average is $10.70 and its 200 day simple moving average is $11.88.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 8,256 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total transaction of $77,358.72. Following the completion of the sale, the director now owns 772,277 shares in the company, valued at $7,236,235.49. This trade represents a 1.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sean Bohen sold 52,328 shares of Olema Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total value of $490,313.36. Following the completion of the transaction, the chief executive officer now owns 298,836 shares of the company’s stock, valued at $2,800,093.32. This trade represents a 14.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 73,036 shares of company stock valued at $684,472. Insiders own 19.40% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of Olema Pharmaceuticals by 105.0% in the third quarter. Barclays PLC now owns 94,915 shares of the company’s stock valued at $1,133,000 after buying an additional 48,614 shares during the period. Conway Capital Management Inc. purchased a new stake in Olema Pharmaceuticals during the third quarter valued at about $119,000. XTX Topco Ltd increased its position in shares of Olema Pharmaceuticals by 103.4% in the third quarter. XTX Topco Ltd now owns 25,332 shares of the company’s stock worth $302,000 after acquiring an additional 12,878 shares in the last quarter. EP Wealth Advisors LLC lifted its position in shares of Olema Pharmaceuticals by 5.2% in the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock valued at $581,000 after acquiring an additional 2,407 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Olema Pharmaceuticals by 10.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after purchasing an additional 97,428 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.